These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 28370306)

  • 1. Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?
    Lestang E; Peterlin P; Le Bris Y; Dubruille V; Delaunay J; Godon C; Theisen O; Blin N; Mahe B; Gastinne T; Garnier A; Touzeau C; Voldoire M; Bene MC; Le Gouill S; Milpied N; Mohty M; Moreau P; Guillaume T; Chevallier P
    Eur J Haematol; 2017 Jul; 99(1):60-69. PubMed ID: 28370306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
    Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years.
    Daghia G; Zabelina T; Zeck G; von Pein UM; Christopeit M; Wolschke C; Ayuk F; Kröger N
    Eur J Haematol; 2019 Oct; 103(4):370-378. PubMed ID: 31306511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis.
    Shahnaz Syed Abd Kadir S; Christopeit M; Wulf G; Wagner E; Bornhauser M; Schroeder T; Crysandt M; Mayer K; Jonas J; Stelljes M; Badbaran A; Ayuketang Ayuk F; Triviai I; Wolf D; Wolschke C; Kröger N
    Eur J Haematol; 2018 Sep; 101(3):305-317. PubMed ID: 29791053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
    Alchalby H; Yunus DR; Zabelina T; Kobbe G; Holler E; Bornhäuser M; Schwerdtfeger R; Bethge W; Kvasnicka HM; Büsche G; Ayuk F; Bacher U; Zander AR; Kröger N
    Br J Haematol; 2012 Apr; 157(1):75-85. PubMed ID: 22280409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically inspired prognostic scoring system (GIPSS) outperforms dynamic international prognostic scoring system (DIPSS) in myelofibrosis patients.
    Kuykendall AT; Talati C; Padron E; Sweet K; Sallman D; List AF; Lancet JE; Komrokji RS
    Am J Hematol; 2019 Jan; 94(1):87-92. PubMed ID: 30390311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.
    Markiewicz M; Dzierzak Mietla M; Wieczorkiewicz A; Mizia S; Helbig G; Kopera M; Bialas K; Rybicka M; Matyja M; Koclega A; Sedlak L; Oleksy T; Raman S; Kyrcz-Krzemien S
    Eur J Haematol; 2016 Mar; 96(3):222-8. PubMed ID: 25899468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A single center experience.
    Schmohl JU; Groh C; Faul C; Vogel W; Möhle R; Wirths S; Schneidawind D; Kanz L; Bethge WA
    Ann Hematol; 2016 May; 95(6):973-83. PubMed ID: 27021303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.
    Ditschkowski M; Elmaagacli AH; Trenschel R; Gromke T; Steckel NK; Koldehoff M; Beelen DW
    Haematologica; 2012 Oct; 97(10):1574-81. PubMed ID: 22491742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.
    Ali H; Aldoss I; Yang D; Mokhtari S; Khaled S; Aribi A; Afkhami M; Al Malki MM; Cao T; Mei M; O'Donnell M; Salhotra A; Pullarkat V; Yang L; Stein AS; Marcucci G; Forman SJ; Nakamura R; Pillai R; Snyder D
    Blood Adv; 2019 Jan; 3(1):83-95. PubMed ID: 30622146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
    Shanavas M; Popat U; Michaelis LC; Fauble V; McLornan D; Klisovic R; Mascarenhas J; Tamari R; Arcasoy MO; Davies J; Gergis U; Ukaegbu OC; Kamble RT; Storring JM; Majhail NS; Romee R; Verstovsek S; Pagliuca A; Vasu S; Ernst B; Atenafu EG; Hanif A; Champlin R; Hari P; Gupta V
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):432-40. PubMed ID: 26493563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.
    Gagelmann N; Eikema DJ; de Wreede LC; Koster L; Wolschke C; Arnold R; Kanz L; McQuaker G; Marchand T; Socié G; Bourhis JH; Mohty M; Cornelissen JJ; Chevallier P; Bernasconi P; Stelljes M; Rohrlich PS; Fanin R; Finke J; Maertens J; Blaise D; Itälä-Remes M; Labussière-Wallet H; Robin M; McLornan D; Chalandon Y; Yakoub-Agha I; Kröger N;
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):e204-e208. PubMed ID: 30930192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Updated recommendations on the use of ruxolitinib for the treatment of myelofibrosis.
    Devos T; Selleslag D; Granacher N; Havelange V; Benghiat FS
    Hematology; 2022 Dec; 27(1):23-31. PubMed ID: 34957926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis.
    Tefferi A; Partain DK; Palmer JM; Slack JL; Roy V; Hogan WJ; Litzow ML; Ketterling RP; Patnaik MM
    Am J Hematol; 2018 May; 93(5):649-654. PubMed ID: 29388258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controversies and dilemmas in allogeneic transplantation for myelofibrosis.
    Shanavas M; Gupta V
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):165-74. PubMed ID: 25189727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
    Ma VT; Boonstra PS; Menghrajani K; Perkins C; Gowin KL; Mesa RA; Gotlib JR; Talpaz M
    Clin Lymphoma Myeloma Leuk; 2018 May; 18(5):e201-e210. PubMed ID: 29574002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis.
    Alchalby H; Badbaran A; Zabelina T; Kobbe G; Hahn J; Wolff D; Bornhäuser M; Thiede C; Baurmann H; Bethge W; Hildebrandt Y; Bacher U; Fehse B; Zander AR; Kröger N
    Blood; 2010 Nov; 116(18):3572-81. PubMed ID: 20489052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis.
    Kröger N; Badbaran A; Holler E; Hahn J; Kobbe G; Bornhäuser M; Reiter A; Zabelina T; Zander AR; Fehse B
    Blood; 2007 Feb; 109(3):1316-21. PubMed ID: 17018857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Challenges in Stem Cell Transplantation in Myelofibrosis.
    Kröger N
    Curr Hematol Malig Rep; 2015 Dec; 10(4):344-50. PubMed ID: 26285891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.